New CLL Drug Heads Toward 2027 Filing
Adults with relapsed or refractory CLL may see a new targeted option after BeOne plans its accelerated-approval submission.
Updated on Nov. 7, 2026 in Cancer

BeOne Medicines raised its 2026 revenue projection to $6.9 billion to $7 billion after third-quarter sales reached $1.4 billion, up 34% from a year earlier. The company also said it plans to seek accelerated approval for tacabrutideg in relapsed or refractory chronic lymphocytic leukemia around mid-2027.
Why it matters
The update signals continued commercial growth for BRUKINSA, a cancer therapy whose U.S. sales topped $1 billion in the quarter, and it gives patients and clinicians a timeline for a new CLL option. The company's filing timetable for tacabrutideg follows an FDA request for additional follow-up, which is why the submission is not expected sooner.
These figures come from BeOne's third-quarter financial results, which report sales growth and an updated annual revenue outlook rather than clinical trial outcomes. Tacabrutideg's accelerated-approval path depends on follow-up data the FDA requested, and that data is not described in the available figures.
The players
BeOne Medicines
A biopharmaceutical company focused on oncology, known for the cancer therapy BRUKINSA and developing tacabrutideg for chronic lymphocytic leukemia.
U.S. Food and Drug Administration (FDA)
The federal agency responsible for approving drugs in the United States, which granted BRUKINSA priority review for treatment-naive mantle cell lymphoma and requested additional follow-up for tacabrutideg.
The details
BRUKINSA is a targeted therapy that blocks Bruton's tyrosine kinase, a protein that cancer B-cells use to survive and multiply. The drug is approved for several B-cell cancers, and BeOne reports that its U.S. sales now exceed $1 billion per quarter. Tacabrutideg is being developed for relapsed or refractory CLL, and BeOne is aiming to file for accelerated approval, a pathway that allows earlier authorization based on an interim measure while confirmatory results are gathered.
Timeline
2026: BeOne raised its full-year revenue projection to $6.9 billion to $7 billion.
Third quarter 2026: Sales reached $1.4 billion, up 34% year over year.
Mid-2027: BeOne plans to submit the tacabrutideg accelerated-approval application for CLL.
Health Landscape
Targeted B-cell therapies have become a central treatment option for CLL and several lymphomas, and newer agents are competing on convenience and tolerability. Under Medicare Part D, higher manufacturer liability and value-based purchasing could reshape how such oncology drugs are priced beyond 2026.
If you or someone you know has CLL, this news signals that a new targeted option may become available around 2027, so it is worth asking an oncologist whether it could be relevant once it is approved. Patients currently in treatment should keep discussing any changes in their care plan with their own clinician rather than changing therapy based on company announcements.
The takeaway
Targeted therapies like BRUKINSA are a growing part of cancer care, and the timeline for new CLL options depends on regulatory feedback. Readers with CLL should review treatment options with their oncologist as new approvals emerge.
What happens next
BeOne plans to submit the tacabrutideg accelerated-approval application for relapsed or refractory CLL around mid-2027.
Further reading
For broader context on treatment advances, explore our Cancer coverage.
Source note: This article includes information reported by TokenPost.





